Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 607

1.

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.

Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20.

2.

Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.

Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1171-8. doi: 10.1161/ATVBAHA.113.302670. Epub 2014 Mar 27.

3.

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice.

Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, Qin W, Miller KS, Hawkins J.

J Lipid Res. 2009 Aug;50(8):1581-8. doi: 10.1194/jlr.M800542-JLR200. Epub 2008 Dec 6.

4.

AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.

Somanathan S, Jacobs F, Wang Q, Hanlon AL, Wilson JM, Rader DJ.

Circ Res. 2014 Aug 29;115(6):591-9. doi: 10.1161/CIRCRESAHA.115.304008. Epub 2014 Jul 14.

5.
6.

Local effects of human PCSK9 on the atherosclerotic lesion.

Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.

J Pathol. 2016 Jan;238(1):52-62. doi: 10.1002/path.4630. Epub 2015 Nov 13.

7.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258
8.

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB.

Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1585-95. doi: 10.1161/ATVBAHA.112.250043. Epub 2012 May 10.

9.

Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.

Miyazawa H, Tabeta K, Miyauchi S, Aoki-Nonaka Y, Domon H, Honda T, Nakajima T, Yamazaki K.

Lipids Health Dis. 2012 Sep 19;11:121. doi: 10.1186/1476-511X-11-121.

10.

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.

Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.

Circulation. 2014 Jul 29;130(5):431-41. doi: 10.1161/CIRCULATIONAHA.113.006720. Epub 2014 May 23. Erratum in: Circulation. 2015 May 5;131(18):e429.

11.

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Maxwell KN, Breslow JL.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5. Epub 2004 Apr 26.

12.

Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.

J Biol Chem. 2012 Jul 6;287(28):23667-77. doi: 10.1074/jbc.M112.350181. Epub 2012 May 16.

13.

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.

Mousavi SA, Berge KE, Leren TP.

J Intern Med. 2009 Dec;266(6):507-19. doi: 10.1111/j.1365-2796.2009.02167.x. Review.

14.

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A.

Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):785-91. doi: 10.1161/ATVBAHA.110.220988. Epub 2011 Jan 27.

15.

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, Jackson S.

J Lipid Res. 2014 Nov;55(11):2370-9. doi: 10.1194/jlr.M053207. Epub 2014 Sep 25.

16.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

17.

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P.

Endocrinology. 2006 Oct;147(10):4985-95. Epub 2006 Jun 22.

PMID:
16794006
18.

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MF, Fazio S.

Cardiovasc Res. 2016 May 15;110(2):268-78. doi: 10.1093/cvr/cvw053. Epub 2016 Mar 15.

19.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL.

Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026. Epub 2011 Nov 25.

PMID:
22176652
20.

Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.

Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A.

Neoplasia. 2012 Dec;14(12):1122-31.

Supplemental Content

Support Center